(RTTNews) - Agilent Technologies Inc. (A) has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, treatment with Opdivo in combination with chemotherapy provides the first and only PD-1-directed treatment to show superior overall survival and progression-free survival when compared to chemotherapy alone, the company said.
"The added indication of PD-L1 IHC 28-8 pharmDx will give physicians in Europe important information to inform first-line treatment decisions for patients with these common and potentially deadly cancers," said Sam Raha, president of the Agilent's Diagnostics and Genomics Group.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
